Rationale Low-efficacy mu opioid receptor agonists may be useful for some clinical indications, but clinically available low-efficacy mu agonists also have low selectivity for mu vs. kappa opioid receptors. NAQ (17-cyclopropylmethyl-3,14ß-dihydroxy-4,5α-epoxy-6α-[(3′-isoquinolyl)acetamido] morphinan) is a novel opioid receptor ligand with lowefficacy at mu receptors and greater mu-receptor selectivity than existing low-efficacy agonists. Objectives This study examined behavioral effects of NAQ in rats using an intracranial self-stimulation (ICSS) procedure that has been used previously to examine other opioids. NAQ effects were examined before, during, and after chronic morphine treatment, and effects of NAQ were compared to effects of nalbuphine and naltrexone. Methods Adult male Sprague-Dawley rats were trained to respond for electrical brain stimulation delivered via electrodes implanted in the medial forebrain bundle. A range of brain stimulation frequencies maintained a wide range of baseline ICSS rates. Effects of NAQ (0.32-10 mg/kg), nalbuphine (1.0 mg/kg), and naltrexone (0.1 mg/kg) were determined before morphine treatment and during treatment with 3.2 and 18 mg/kg/day morphine. NAQ effects were also redetermined beginning 2 weeks after termination of morphine treatment.
Introduction
Mu opioid receptor agonists are used for a range of clinical applications that include treatment of pain, diarrhea, and cough, and they are also used as maintenance medications to treat opioid addiction (Gutstein and Akil 2006; Negus and Banks 2013) . Two important determinants of opioid action are selectivity for and efficacy at mu opioid receptors. Regarding selectivity, drugs may bind not only to mu receptors but also to kappa or delta opioid receptors or to non-opioid receptors (Emmerson et al. 1994; Raynor et al. 1994) . Regarding efficacy, drugs vary along a continuum from high to low efficacy at mu receptors, and mu receptor ligands may also function as antagonists or inverse agonists (Emmerson et al. 1996; Selley et al. 1998) . For mu agonists that are currently available clinically, the most selective mu agonists also have high efficacy at mu receptors (e.g., methadone and fentanyl) (Emmerson et al. 1996; Raynor et al. 1994; Selley et al. 1998) . Conversely, mu agonists with lower efficacy at mu receptors (e.g., nalbuphine, pentazocine, and butorphanol) also have low selectivity for mu receptors, especially for mu vs. kappa opioid receptors (Emmerson et al. 1994 (Emmerson et al. , 1996 Peng et al. 2007; Raynor et al. 1994; Selley et al. 1998 ). Lowefficacy mu agonists may have clinical value for some indications because they might retain sufficient efficacy to produce therapeutic effects such as analgesia against modest pain or alleviation of opioid withdrawal, but they might lack sufficient efficacy to produce some side effects such as significant respiratory depression or lethality (Gutstein and Akil 2006; Hoskin and Hanks 1991; Negus and Banks 2013) . However, kappa opioid receptors mediate dysphoric subjective effects and some other undesirable effects (Pfeiffer et al. 1986; Walsh et al. 2001) , and kappa-mediated effects may be one factor that limits clinical utility of existing low-efficacy opioids. Identification of more selective low-efficacy mu agonists might therefore be useful for some clinical indications.
NAQ (17-cyclopropylmethyl-3,14ß-dihydroxy-4,5α-epoxy-6α-[(3′-isoquinolyl) acetamido]morphinan) has recently been synthesized as a novel opioid receptor ligand, and in vitro studies of receptor binding and functional efficacy suggest that it functions as a low-efficacy mu agonist with greater mu selectivity than existing clinically available lowefficacy mu agonists (Li et al. 2009 ). In binding studies, NAQ displays nearly 50-fold selectivity for mu vs. kappa receptors and even greater selectivity for mu vs. delta receptors (Li et al. 2009 ). Conversely, nalbuphine, pentazocine, and butorphanol all display little or no selectivity for mu vs. kappa receptors and similar or less selectivity than NAQ for mu vs. delta receptors (Emmerson et al. 1994; Li et al. 2009; Peng et al. 2007; Raynor et al. 1994) . In functional studies of agoniststimulated GTPγS binding, NAQ displays low efficacy similar to that of nalbuphine, pentazocine, and butorphanol at mu receptors (Emmerson et al. 1996; Li et al. 2009; Selley et al. 1998) but weaker efficacy than these compounds at kappa receptors (Peng et al. 2007; Remmers et al. 1999; Yuan et al. 2011) . The mu selectivity and very low kappa efficacy of NAQ both contribute to its potential for in vivo selectivity as a low-efficacy mu agonist.
This study evaluated behavioral effects of NAQ in rats using intracranial self-stimulation (ICSS), a behavioral procedure that has been used previously to examine other opioids that vary in selectivity for and efficacy at opioid receptors (Altarifi et al. 2012 Altarifi and Negus 2011; Negus et al. 2010; Pereira Do Carmo et al. 2009; Todtenkopf et al. 2004 ). This procedure has been useful to dissociate both efficacy and receptor selectivity of opioid agonists, and also because drug effects on ICSS can be interpreted in terms of abuse potential, a key side effect of opioid analgesics Negus and Miller 2014; Vlachou and Markou 2011; Wise 1996) . NAQ effects were examined before, during, and after a regimen of repeated morphine treatment because previous studies found that a history of opioid exposure can enhance abuse-related effects of opioids on ICSS (Altarifi and Negus 2011; Altarifi et al. 2013) . Also, relief of morphine withdrawal by NAQ may suggest consideration of NAQ to treat opioid dependence (Negus and Banks 2013) . Lastly, effects of NAQ were compared to effects of nalbuphine and naltrexone, two clinically available mu opioids with low mu vs. kappa selectivity and low or inverse efficacy at mu receptors, respectively (Emmerson et al. 1996; Raynor et al. 1994 ).
Methods
Subjects Six male Sprague-Dawley rats (Harlan, Fredrick, MD, USA) weighing 310-350 g at the time of surgery were individually housed and maintained on a 12-h light/dark cycle with lights on from 6:00 a.m. to 6:00 p.m. Rats had free access to food and water except during testing. Animal maintenance and research were in compliance with National Institutes of Health guidelines on care and use of animal subjects in research, and all animal use protocols were approved by the Virginia Commonwealth University Institutional Care and Use Committee.
Apparatus and training Training and testing procedures were identical to those described previously for other opioid agonists . Briefly, experiments were conducted in six operant conditioning chambers (Model ENV-007-VP-CT, Med Associates) equipped with a single response lever, stimulus lights, a house light, and an ICSS stimulator (Model SG-510, Med Associates) that delivered brain stimulation via an electrode implanted in the left medial forebrain bundle at the level of the lateral hypothalamus (2.8 mm posterior and 1.7 mm lateral from the bregma, and 8.8 mm below the skull). The house light was illuminated during behavioral sessions, and responding under a FR 1 schedule produced a 0.5-s train of 0.1-ms square-wave cathodal pulses (0.1-ms pulse duration) together with 0.5 s illumination of stimulus lights over the response lever. The terminal schedule consisted of sequential 10-min components. During each component, one of a descending series of 10 current frequencies was presented (158-56 Hz in 0.05-log increments), with a 60-s trial at each frequency. Each frequency trial consisted of a 10-s time out, during which five noncontingent stimulations were delivered at the frequency available during that trial, followed by a 50-s "response" period, during which responding produced electrical stimulation. Training was considered to be complete when two criteria were met. First, rats had to respond at rates greater than 50 percent maximum control rate (%MCR) (see Data analysis) during the first three frequency trials of all components for three consecutive days. Second, rats were then tested with saline until these injections had no effect on frequency-rate curves as determined by two-way analysis of variance (ANOVA) (see Data analysis).
Testing Once training was complete, "predrug baseline" sessions were conducted over a period of three consecutive days to establish baseline ICSS performance before administration of any drug. Each predrug baseline session consisted of three components as described above. After collecting predrug baseline data, testing proceeded in four phases to evaluate NAQ effects before chronic morphine (phase 1), during daily treatment with 3.2 mg/kg/ day morphine (phase 2), and 18 mg/kg/day morphine (phase 3), and beginning 2 weeks after termination of morphine treatment (phase 4). During each phase, each rat received vehicle and NAQ (0.32-10 mg/kg) in a mixed dose order followed by testing with 1.0 mg/kg nalbuphine and 0.1 mg/kg naltrexone in that order. These reference doses of nalbuphine and naltrexone were selected based on results from previous studies (Altarifi et al. 2012 .
The first phase of testing started immediately after the predrug baseline sessions and lasted for 15 days. Daily ICSS sessions in this and all subsequent phases consisted of three consecutive daily baseline components followed first by a 30 min time out and then by two ICSS test components. Saline or drug was administered at the beginning of the time out. Thus, ICSS was assessed twice each day: once during the daily baseline components before that day's injection (and approximately 23 h after the previous day's injection) and once during the test components that began 30 min after that day's injection. After the last test component, subjects were removed from the test chambers and returned to their home cages. Test sessions with each dose of NAQ, nalbuphine, or naltrexone were separated by at least 3 days. Saline was administered on intervening days. ICSS sessions were sometimes omitted on weekends, but injections were delivered daily.
The second phase started with a 7-day maintenance period, during which 3.2 mg/kg/day morphine was administered during the time out of each daily ICSS session. On day 8, test sessions resumed, and drug effects were redetermined using the same dose order and intervals as the first phase. In addition, two additional test days were also added during which the rats were tested with 0.1 mg/kg naltrexone+1.0 mg/kg NAQ or 0.1 naltrexone+1.0 mg/kg nalbuphine. For these tests, naltrexone was administered 5 min before NAQ or nalbuphine, which was administered 30 min before onset of test ICSS components. On days that subjects did not receive a test drug, they received 3.2 mg/kg morphine. As in phase 1, test sessions were separated by at least 3 days, so that each test session was preceded by at least 2 days of treatment with the chronic morphine dose. Also, when subjects were tested with vehicle, they received a supplemental dose of 3.2 mg/kg morphine after the ICSS test session on that day before returning to their home cages. Phase 2 lasted 25 days.
The third phase began with a gradual increase in the morphine dose administered during the time out of consecutive daily ICSS sessions. Subjects received 5.6 mg/kg/day morphine for 2 days, followed by 10 mg/kg/day morphine for 4 days, and 18 mg/kg/day for the remainder of the third phase. Once the terminal dose of 18 mg/kg/day morphine was achieved, it was maintained for 7 days. Subsequently, test sessions resumed, and drug effects were redetermined using the same dose order and intervals as the first phase. Subjects in this phase received 18 mg/kg/day morphine on the days that they did not receive a test drug, and 18 mg/kg morphine was also administered at the end of test sessions during which vehicle or low NAQ doses (0.32-1.0 mg/kg) were tested. Phase 3 lasted 26 days.
At the end of the third phase, daily morphine injections were terminated, and ICSS sessions and drug treatments were suspended for 2 weeks. Training was then resumed for 3 days, after which NAQ effects were redetermined using the same dose order and intervals as the first phase. Nalbuphine and naltrexone were not tested during this phase.
Fecal bolus production During repeated 18 mg/kg/day morphine, operant chambers were scored for the presence of fecal boli at the end of each test session. The number of subjects with two or more fecal boli was counted for each treatment as a sign of enhanced gastrointestinal transit often associated with morphine withdrawal.
Data analysis The primary dependent variable was the reinforcement rate in stimulations/trial during each frequency trial. To normalize these raw data, reinforcement rates from each trial in each rat were converted to percent maximum control rate (%MCR) for that rat. The maximum control rate was determined for each rat during the predrug baseline sessions at the beginning of the experiment. The first component from these sessions (and from all other sessions) was considered to be an acclimation component, and data were discarded. The maximum control rate was defined as the mean of the maximal rates observed during any frequency trial of the second and third components of the three predrug baseline sessions (six total predrug baseline components). Subsequently, %MCR for each trial was calculated as (reinforcement rate during a frequency trial÷maximum control rate)×100. Graphs show mean frequency-rate curves, with brain stimulation frequency on the abscissa and ICSS rate expressed as %MCR on the ordinate.
Frequency-rate curves from test sessions during each phase of the study were submitted for statistical analysis. As noted above, these frequency-rate curves were assessed twice on each test day: once during daily baseline components before that day's injection (and approximately 23 h after the previous day's injection) and again during test components that began 30 min after that day's injection. Daily baseline data and test data from test sessions were analyzed separately. The daily baseline data provided information on changes in baseline ICSS produced by the chronic treatment (saline, 3.2 mg/kg/ day morphine, 18 mg/kg/day morphine, or protracted morphine withdrawal). During chronic morphine treatment, daily baseline components were conducted approximately 23 h after the most recent morphine injection, and as a result, these results provided data on changes in ICSS produced by 23 h withdrawal from the morphine maintenance dose. Daily baseline data from test days within each phase were averaged across all rats to yield mean baseline ICSS data during chronic treatment with saline, 3.2 mg/kg/day morphine, 18/mg/kg/day morphine, and protracted morphine withdrawal. Mean daily baseline data during each phase were compared to the predrug baseline data using two-way ANOVA, with phase of chronic treatment as one factor and ICSS frequency as the other factor. A significant ANOVA was followed by a Holm-Sidak post hoc test, and the criterion for significance was set at P<0.05. To permit within-subject analysis, data were included only for those rats that completed all four phases of chronic morphine treatment (N=5; one rat lost its head cap and electrode at the end of phase 2 and was not tested in phases 3 and 4).
Test data from each test session were averaged across rats within each condition and analyzed to assess drug effects on ICSS frequency-rate curves during each phase of chronic morphine/vehicle treatment. Within each phase, ICSS test data for vehicle and NAQ were compared by two-way ANOVA, with NAQ dose as one factor and ICSS frequency as the other factor. A similar approach was used to compare effects of vehicle, nalbuphine, and naltrexone. A significant ANOVA was followed by a Holm-Sidak post hoc test, and the criterion for significance was set at P<0.05. Data were included for all rats that completed a given phase (N = 6 for saline and 3.2 mg/kg/day morphine, N=5 for 18 mg/kg/day morphine and post-morphine).
To provide an additional summary measure of baseline and test ICSS performances, the total number of stimulations per component was calculated as the average of the total stimulations delivered across all 10 frequency trials of each component. Baseline and test data were expressed as a percentage of the total stimulations per component earned during the predrug baseline components (% control). Thus, % control was calculated as (mean total stimulations during daily baseline or test components÷ mean total stimulations during predrug baseline components)×100.
Drugs Morphine sulfate and naltrexone HCl were provided by the National Institute on Drug Abuse Drug Supply Program (Bethesda, MD). Nalbuphine HCl was provided by Dr. Kenner Rice (Chemical Biology Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD). NAQ (17-cyclopropylmethyl-3,14ß-dihydroxy-4,5α-epoxy-6α-[(3′-isoquinolyl)acetamido] morphinan) was synthesized in Dr. Zhang's laboratory as described previously (Li et al. 2009 ). Morphine, nalbuphine, and naltrexone were dissolved in saline, while NAQ was dissolved in water. All doses are expressed in the salt forms above, and all injections were delivered subcutaneously in a volume of 1 ml/kg body weight.
Results
Baseline ICSS before, during, and after chronic morphine During predrug baseline sessions, the mean±SEM maximum control rate (MCR) for all rats in the study was 64.1±7.4 stimulations per trial, and the mean±SEM control number of total stimulations delivered across all frequencies was 344.0± 55.0. Figure 1 shows baseline frequency-rate ICSS curves before treatment and during each phase of chronic morphine treatment. There were significant main effects of frequency [F(9,36)=95.8; P<0.001] and treatment phase [F(4,16)=9.1; P<0.001] and a significant phase X frequency interaction [F(36,144)=4.0; P<0.001]. Electrical brain stimulation maintained a frequency-dependent increase in ICSS rates before initiation of any drug treatments (predrug baseline), and chronic vehicle did not significantly alter ICSS. Chronic treatment with 3.2 mg/kg/day morphine slightly decreased ICSS relative to the predrug baseline (significant at 89 Hz), and 18 mg/kg/day morphine produced a further decrease in ICSS (significant at 89-126 Hz). These baseline ICSS frequencyrate curves were determined approximately 23 h after the most recent morphine injection on the previous day, and they show the effects of spontaneous 23 h withdrawal from that morphine maintenance dose. ICSS partially recovered at 2 weeks after termination of morphine treatment, although ICSS rates were still significantly decreased at three frequencies (89-112 Hz).
Effects of NAQ on ICSS before, during, and after chronic morphine Figure 2 shows effects of NAQ on ICSS. During vehicle treatment, NAQ produced weak effects that were not monotonically related to dose (significant main effect of frequency [F(9,45)=66.7; P<0.001], no significant main effect of dose [F(4,20) =1.8; P=0.178], and a significant interaction [F(36,180)=2.0; P=0.001]). Thus, exclusive increases in ICSS were produced by NAQ doses of 0.32 mg/kg (71 Hz) and 3.2 mg/kg (63-79 Hz), whereas the highest dose of 10 mg/kg produced biphasic effects (increased ICSS at 71 Hz and decreased ICSS at 158 Hz). A dose of 1.0 mg/kg NAQ did not significantly alter ICSS at any frequency. Repeated treatment with 3.2 mg/kg/day morphine eliminated expression of the rate-decreasing effects of NAQ and enhanced the dose-dependence and magnitude of NAQ's rateincreasing effects (significant main effects of frequency [F(9,45) = 32.5; P < 0.001] and dose [F(4,20) = 17.7; P < 0.001] and a significant interaction [F(36,180)= 2.5; P<0.001]). For example, 10 mg/kg NAQ increased ICSS at frequencies of 63-100 Hz and did not decrease ICSS at any frequency (Fig. 2c, d ). During treatment with 18 mg/kg/day morphine, NAQ produced similar effects consisting of exclusive increases in ICSS across all NAQ doses (significant main effects of frequency [F(9,36)=43.7; P<0.001] and dose [F(4,16) = 3.4; P = 0.033] and a significant interaction [F(36,144)=1.8; P=0.007]). However, the magnitude of NAQ effects was generally smaller during treatment with 18 than that with 3.2 mg/kg/day morphine. For example, during treatment with 3.2 mg/kg/morphine, 10 mg/kg NAQ increased ICSS at six frequencies (63-100 Hz), but during treatment with 18 mg/kg morphine, the same NAQ dose only increased ICSS at two frequencies (100-112 Hz). Two weeks after termination of morphine treatment, all NAQ doses continued to produce a significant increase in ICSS (significant main effects of frequency [F(9,36)=19.4; P<0.001] and dose [F(4,16) = 8.2; P < 0.001] but no significant interaction [F(36,144)=1.3; P=0.151]).
To evaluate the role of opioid receptors in NAQ-induced facilitation of ICSS, 0.1 mg/kg naltrexone was administered as a pretreatment to 1.0 mg/kg NAQ during treatment with 3.2 mg/kg/day morphine, and results are shown in Fig. 3 . Naltrexone blocked NAQ-induced facilitation of ICSS at a naltrexone dose that had no effect alone (significant main effect of frequency [F(9,45) Figure 4 compares the effects of 1.0 mg/kg nalbuphine and 0.1 mg/kg naltrexone on ICSS before and during chronic morphine. In all phases, 1.0 mg/kg nalbuphine produced significant facilitation of ICSS compared to vehicle, whereas 0.1 mg/kg naltrexone failed to produce any significant changes. As observed with NAQ, 0.1 mg/kg naltrexone blocked nalbuphine-induced facilitation of ICSS during chronic treatment with 3.2 mg/kg/day morphine. ANOVA results for each panel of Fecal bolus production Fecal boli were counted after test sessions during treatment with 18 mg/kg/day morphine, and Fig. 1 Baseline ICSS performance before, during, and after chronic morphine treatment. ICSS curves were analyzed during predrug baseline sessions (grey dashed line) and before test drug administration during each phase of morphine exposure. The left panel shows ICSS frequencyrate curves. Abscissae: frequency of electrical brain stimulation in hertz (log scale). Ordinates: ICSS rate expressed as percent maximum control rate (%MCR). Filled symbols indicate frequencies at which ICSS rates were lower than those observed during the predrug baseline components as determined by the Holm-Sidak post-hoc test following a significant two-way ANOVA. Right panel shows summary data for the total number of stimulations per test component expressed as a percentage of total predrug baseline control stimulations. Abscissa: daily morphine dose in mg/kg/day during each phase of testing. Ordinate: percent control stimulations per test component. Arrows indicate the presence and direction of significant differences from predrug baseline as determined by analyses of frequency-rate data in the left panel, such that downward arrows indicate significant depression of ICSS at ≥1 frequency of the frequency-rate curve. All points show mean±SEM for the five rats that completed all phases of the study; one rat lost its head cap during treatment with 18 mg/kg/day morphine and is not included in this figure Fig. 2 Effects of NAQ on ICSS before, during, and after chronic morphine treatment. NAQ doses (or vehicle) were administered during treatment with repeated vehicle (a, b), repeated 3.2 mg/kg/day morphine (c, d), repeated 18 mg/kg/day morphine (e, f), or beginning 2 weeks after termination of morphine treatment (g, h) . Left panels show full frequency-rate curves. Left abscissae: frequency of electrical brain stimulation in hertz (log scale). Left ordinates: ICSS rate expressed as percent maximum control rate (%MCR). Filled symbols indicate frequencies at which ICSS rates after NAQ were different than those observed after vehicle, as determined by the Holm-Sidak post-hoc test following a significant two-way ANOVA. Summary data in the right panels show the total number of stimulations per test component expressed as a percentage of total predrug baseline control stimulations. Abscissae: dose of NAQ in mg/kg. Ordinates: percent control stimulations per test component. Upward and/or downward arrows indicate the presence and direction of significant differences from vehicle as determined by analyses of frequency-rate data in the left panel, such that upward arrows indicate significant facilitation of ICSS at ≥1 frequency, and downward arrows indicate significant depression of ICSS at ≥1 frequency of the frequency-rate curve. All points show mean±SEM for six rats (panels a-d) or five rats (panels e-h) the number of rats with two or more fecal boli was counted for each treatment. No rats met this criterion after vehicle treatment, and all rats met this criterion after naltrexone treatment. No more than two rats met this criterion during treatment with any NAQ dose, and similarly, only two rats met this criterion after 1.0 mg/kg nalbuphine.
Effect of nalbuphine and naltrexone on ICSS

Discussion
This study evaluated effects of the novel opioid receptor ligand NAQ on ICSS in rats before, during, and after a regimen of chronic morphine treatment. There were three main findings. First, the profile of NAQ effects throughout testing was consistent with its in vitro profile as a selective and low-efficacy mu agonist. Second, NAQ produced weak and inconsistent ICSS facilitation in opioid-naïve rats, but it produced dose-dependent and more robust ICSS facilitation in opioid-experienced rats both during and after morphine treatment. Insofar as ICSS facilitation is predictive of abuse potential, these results suggest that NAQ might have weak abuse liability in opioid-naïve subjects and higher abuse liability in subjects with histories of opioid exposure. Lastly, repeated daily morphine treatment was associated with a withdrawalassociated depression of ICSS, and NAQ had sufficient muagonist efficacy to reverse this withdrawal effect. This finding suggests that NAQ may be useful as a low-efficacy and relatively safe strategy for treatment of opioid withdrawal and addiction.
NAQ as a low-efficacy mu agonist Results of this study are consistent with the characterization of NAQ as a low-efficacy mu agonist. We have reported previously that other mu opioid receptor ligands produce efficacy-dependent effects on ICSS in opioid-naive rats (Altarifi et al. 2012 Altarifi and Negus 2011) . Specifically, mu antagonists such as naltrexone and ß-funaltrexamine have little effect on ICSS but block effects of mu agonists. Low-efficacy mu agonists such as nalbuphine produce weak facilitation of low ICSS rates maintained by low frequencies of brain stimulation and weak depression of high ICSS rates maintained by high frequencies of brain stimulation. Finally, high-efficacy mu agonists such as morphine, fentanyl, or methadone also produce weak facilitation of low ICSS rates maintained by low frequencies of brain stimulation; however, in comparison to low-efficacy agonists, high-efficacy mu agonists produce more robust decreases in high ICSS rates maintained by high frequencies of brain stimulation. In the present study, NAQ effects observed prior to initiation of morphine treatment resembled nalbuphine effects in opioid-naive rats reported here with 1.0 mg/kg nalbuphine or previously with a wider nalbuphine dose range (Altarifi et al. 2012 .
Mu agonists also display a characteristic change in effects on ICSS after regimens of opioid exposure (Koob et al. 1975; . For example, we reported previously that a regimen of morphine exposure identical to that used here produced tolerance to ICSS rate-decreasing effects and enhanced expression of ICSS rate-increasing effects of both low-and high-efficacy mu agonists (Altarifi and Negus 2011; Altarifi et al. 2013) . Consistent with these previous results with other mu agonists, repeated morphine also produced tolerance to any rate-decreasing effects and enhanced expression of rate-increasing effects of NAQ in this study. The enhanced expression of rate-increasing effects was especially evident during treatment with the intermediate morphine dose of 3.2 mg/kg/day morphine and appeared weaker during treatment with the higher dose of 18 mg/kg/ day morphine. These results suggest that treatment with high morphine doses may produce tolerance not only to ratedecreasing effects of NAQ but also to its abuse-related, rateincreasing effects.
The characterization of NAQ as a low-efficacy mu-selective agonist is also supported by two other sources of data. First, NAQ-induced facilitation of ICSS was blocked by a naltrexone dose shown previously to block ICSS effects of other mu agonists (Altarifi et al. 2012) . Second, the profile of NAQ effects observed here did not resemble the profile of ICSS effects produced by agonists at either kappa opioid receptors (Beguin et al. 2008; Negus et al. 2010 Negus et al. , 2012a Todtenkopf et al. 2004) or delta opioid receptors (Negus et al. 2012b; Pereira Do Carmo et al. 2009 ). In contrast to mu agonists, systemically administered kappa and delta agonists produce only depression of ICSS, and although repeated treatment may produce tolerance to these rate-decreasing effects, it does not unmask expression of rate-increasing effects .
In vitro studies have suggested that NAQ differs from other low-efficacy mu agonists such as nalbuphine in the degree of its selectivity for mu vs. kappa and delta opioid receptors (Li et al. 2009 ). Previous studies have not found evidence for a role of non-mu opioid receptors in mediating nalbuphine effects on ICSS, and NAQ and nalbuphine effects on ICSS are similar in studies conducted so far. However, nalbuphine has been reported to produce effects mediated by kappa opioid receptors (Pick et al. 1992) or other opioid receptor types (e.g., nociceptin/ orphanin FQ receptors; Gear et al. 2014 ) under other conditions in rodents. Future studies will be required to investigate the degree to which NAQ might lack these non-mu effects. Implications for expression and treatment of abuse ICSS is one preclinical procedure that has been used to assess abuse potential of drugs in laboratory animals, and drug-induced facilitation of low ICSS rates maintained by low brain stimulation frequencies or intensities is often interpreted as evidence for abuse potential Negus and Miller 2014; Vlachou and Markou 2011; Wise 1996) . From this perspective, the present results suggest that NAQ has sufficient efficacy at mu opioid receptors to produce abuse-related effects in other preclinical procedures such as drug self-administration and to have some abuse liability in humans. For example, NAQ effects on ICSS were similar to those of nalbuphine, and nalbuphine maintains selfadministration by laboratory animals (Balster and Lukas 1985; Steinfels et al. 1981) and is occasionally abused by humans (Preston and Jasinski 1991; Wines et al. 1999) . However, behavioral economic studies in rhesus monkeys suggest that nalbuphine functions as a weaker reinforcer than higherefficacy mu agonists (Hursh and Winger 1995) , and the present ICSS results suggest that abuse-related effects of NAQ are similar to those of nalbuphine.
The present study also found that NAQ reversed the depression of ICSS produced by spontaneous morphine withdrawal. Specifically, in agreement with previous studies (Altarifi and Negus 2011; Altarifi et al. 2013 ), once-per-day treatment with escalating morphine doses produced a dosedependent depression in ICSS measured 23 h after each daily morphine injection, and this ICSS depression partially recovered within 2 weeks after termination of morphine treatment. Depression of ICSS associated with withdrawal from opioids or other abused drugs has been interpreted as a potential sign of withdrawal-associated anhedonia, which may contribute to continued drug use and addiction (Kenny et al. 2006; Liu and Schulteis 2004; Stoker and Markou 2011) . Accordingly, NAQ reversal of withdrawal-induced depression of ICSS suggests that NAQ may be useful as a tool in treatment of opioid dependence to prevent or reverse anhedonic signs of opioid withdrawal. Existing treatments for opioid withdrawal include the antagonist naltrexone, the intermediate-efficacy agonist buprenorphine, and the high-efficacy agonist methadone (Gutstein and Akil 2006; Kreek et al. 2002; Negus and Banks 2013) . One advantage of NAQ as a complement to these existing medications is its relative efficacy between naltrexone and buprenorphine. Thus, unlike naltrexone, NAQ has sufficient mu receptor efficacy to reverse withdrawal-induced depression of ICSS . Perhaps because of its weak but measurable efficacy at mu receptors, NAQ also precipitated weaker somatic withdrawal signs than naltrexone in morphine-dependent mice (Yuan et al. 2011 ) and weaker withdrawal-associated activation of gastrointestinal transit than naltrexone in morphine-dependent rats in the present study. However, NAQ has lower efficacy at mu receptors than either buprenorphine or methadone (Emmerson et al. 1996; Li et al. 2009; Selley et al. 1998 ) and might therefore be less likely than these higher-efficacy mu agonists to produce undesirable side effects such as sedation or respiratory depression. The low efficacy of NAQ to produce ICSS ratedecreasing effects in this study in both opioid-naive and opioid-experienced subjects is consistent with this potential for NAQ to be safer than higher-efficacy mu agonists.
